Final COMBI-I analysis in BRAF V600-mutant advanced melanoma (trial missed its primary PFS end point): median OS 61.5 vs 41.6 months with spartalizumab vs placebo added to dabrafenib-trametinib (HR 0.760); grade ≥3 TRAEs 57.3% vs 36.7%.
RCTn = 532
Ribas et al. COMBI-I: Long-Term Overall Survival With Spartalizumab Plus Dabrafenib and Trametinib in BRAF V600-Mutant Advanced Melanoma